Iman Kiani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iman Kiani has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
2 shared publications Alisa Mohebbi
School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
2 shared publicationsAydin Taghilou
Radiology Department, Adl Hospital, Tehran, Iran
2 shared publicationsAbhishek Saha
Medical Sciences Division, University of Oxford, Oxford, UK
1 shared publicationAfshin Mohammadi
Department of Radiology, Faculty of Medicine, Urmia University of Medical Science, Urmia, Iran
1 shared publicationAhmadreza Samimi
Students' Scientific Research Center Tehran University of Medical Sciences Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by Wiley in Human Brain Mapping
- Vol. 47 (14) , e70649
DTI ‐ ALPS as a Biomarker of Small Vessel Disease Progression and Amyloid‐β in Normal Aging: A 3‐Year Longitudinal Study
Cerebral small vessel disease (SVD) is a leading cause of stroke, vascular cognitive impairment, and functional decline in older adults. Emerging experimental and translational data implicate glymphatic dysfunction in SVD pathogenesis and in vascular amyloid accumulation. The analysis along the perivascular space (ALPS) index, derived from diffusion tensor imaging (DTI), noninvasively estimates water diffusivity along perivascular pathways and has been proposed as an indirect imaging marker related to glymphatic function. In this study, we aim to determine whether the baseline DTI‐ALPS index is associated with baseline SVD burden and subsequent longitudinal changes in SVD markers and amyloid‐β deposition in cognitively normal aging. We analyzed 204 cognitively normal participants from the Harvard Aging Brain Study with baseline and follow‐up visits separated by 3 years. Primary MRI SVD outcomes were intracranial‐volume–normalized white matter hyperintensities (WMH/ICV), and visual SVD ratings (Fazekas, ARWMC, perivascular space, and BOMBS [microbleed scale]). Secondary outcomes included cortical amyloid PET burden (PIB_FS_DVR_FLR). We tested the effects of time, baseline ALPS ( z ‐scored), and the time‐ALPS interaction using Bayesian mixed‐effects models with subject‐specific random intercepts adjusted for baseline age, sex, and education; amyloid models were additionally adjusted for APOE4 status. Continuous outcomes were modeled with Gaussian mixed‐effects models, binary outcomes with Bernoulli mixed‐effects models, and ordinal outcomes with Bayesian cumulative mixed‐effects models. In a sensitivity analysis, ALPS was recalculated after excluding voxels with λ 2 / λ 3 > 1.8, and the models were repeated using the crossing‐fiber‐adjusted index. Posterior means and 95% HDIs were the primary summaries. Multiplicity was controlled using the Benjamini–Hochberg false discovery rate procedure, and the resulting FDR‐adjusted two‐sided posterior tail‐area p ‐analogues are reported as p corrected . Over the 3‐year follow‐up, SVD and amyloid‐β burden increased: WMH/ICV ( β = 0.096, 95% HDI [0.069, 0.121], p corrected < 0.001), cortical amyloid‐β ( β = 0.130, 95% HDI [0.106, 0.152], p corrected < 0.001), Fazekas ( β = 0.320, 95% HDI [0.088, 0.541], p corrected = 0.010), ARWMC ( β = 0.404, 95% HDI [0.165, 0.649], p corrected = 0.004), basal ganglia ( β = 0.318, 95% HDI [0.079, 0.546], p corrected = 0.010), and centrum semiovale ( β = 0.244, 95% HDI [0.026, 0.450], p corrected = 0.025). PVS scores also increased over time. Higher baseline ALPS was associated with lower Fazekas severity ( β = −0.742, 95% HDI [−1.281, −0.201], p corrected = 0.026) and with attenuated amyloid accumulation over time ( β = −0.025, 95% HDI [−0.049, −0.001], p corrected = 0.039). In a sensitivity analysis excluding voxels with a high likelihood of substantial fiber crossing, the ALPS‐by‐time interaction for amyloid burden remained significant ( β = −0.028, 95% HDI [−0.052, −0.003], p corrected = 0.022), whereas the baseline association with Fazekas severity was attenuated ( β = −0.413, 95% HDI [−0.966, 0.181], p corrected = 0.751). Higher baseline WMH/ICV was associated with poorer baseline global cognition (PACC5) ( β = −0.092, 95% HDI [−0.177, −0.011], p corrected = 0.036), processing speed ( β = −0.116, 95% HDI [−0.223, −0.010], p corrected = 0.036), and executive function ( β = −0.144, 95% HDI [−0.251, −0.029], p corrected = 0.035). Higher baseline amyloid burden was associated with steeper PACC5 decline ( β = −0.065, 95% HDI [−0.096, −0.033], p corrected < 0.001). In cognitively normal older adults, higher conventional baseline ALPS was associated with lower Fazekas severity, although attenuation after crossing‐fiber adjustment indicates that this cross‐sectional relationship was sensitive to the microstructural composition of the ALPS regions. In contrast, higher baseline ALPS was associated with slower short‐term amyloid‐β accumulation, and this longitudinal association remained significant after crossing‐fiber adjustment. Greater baseline amyloid burden was associated with more rapid decline in global cognition, whereas higher baseline WMH volume was associated with poorer baseline global cognition, processing speed, and executive function. These findings support ALPS as a candidate noninvasive diffusion marker associated with longitudinal amyloid‐related change, while emphasizing the need for further validation of its relationship with SVD burden and its biological specificity.
- 20 September 2026
- Published by Wiley in Human Brain Mapping
- Vol. 47 (14) , e70649
Open AccessDTI ‐ ALPS as a Biomarker of Small Vessel Disease Progression and Amyloid‐β in Normal Aging: A 3‐Year Longitudinal Study
Cerebral small vessel disease (SVD) is a leading cause of stroke, vascular cognitive impairment, and functional decline in older adults. Emerging experimental and translational data implicate glymphatic dysfunction in SVD pathogenesis and in vascular amyloid accumulation. The analysis along the perivascular space (ALPS) index, derived from diffusion tensor imaging (DTI), noninvasively estimates water diffusivity along perivascular pathways and has been proposed as an indirect imaging marker related to glymphatic function. In this study, we aim to determine whether the baseline DTI‐ALPS index is associated with baseline SVD burden and subsequent longitudinal changes in SVD markers and amyloid‐β deposition in cognitively normal aging. We analyzed 204 cognitively normal participants from the Harvard Aging Brain Study with baseline and follow‐up visits separated by 3 years. Primary MRI SVD outcomes were intracranial‐volume–normalized white matter hyperintensities (WMH/ICV), and visual SVD ratings (Fazekas, ARWMC, perivascular space, and BOMBS [microbleed scale]). Secondary outcomes included cortical amyloid PET burden (PIB_FS_DVR_FLR). We tested the effects of time, baseline ALPS ( z ‐scored), and the time‐ALPS interaction using Bayesian mixed‐effects models with subject‐specific random intercepts adjusted for baseline age, sex, and education; amyloid models were additionally adjusted for APOE4 status. Continuous outcomes were modeled with Gaussian mixed‐effects models, binary outcomes with Bernoulli mixed‐effects models, and ordinal outcomes with Bayesian cumulative mixed‐effects models. In a sensitivity analysis, ALPS was recalculated after excluding voxels with λ 2 / λ 3 > 1.8, and the models were repeated using the crossing‐fiber‐adjusted index. Posterior means and 95% HDIs were the primary summaries. Multiplicity was controlled using the Benjamini–Hochberg false discovery rate procedure, and the resulting FDR‐adjusted two‐sided posterior tail‐area p ‐analogues are reported as p corrected . Over the 3‐year follow‐up, SVD and amyloid‐β burden increased: WMH/ICV ( β = 0.096, 95% HDI [0.069, 0.121], p corrected < 0.001), cortical amyloid‐β ( β = 0.130, 95% HDI [0.106, 0.152], p corrected < 0.001), Fazekas ( β = 0.320, 95% HDI [0.088, 0.541], p corrected = 0.010), ARWMC ( β = 0.404, 95% HDI [0.165, 0.649], p corrected = 0.004), basal ganglia ( β = 0.318, 95% HDI [0.079, 0.546], p corrected = 0.010), and centrum semiovale ( β = 0.244, 95% HDI [0.026, 0.450], p corrected = 0.025). PVS scores also increased over time. Higher baseline ALPS was associated with lower Fazekas severity ( β = −0.742, 95% HDI [−1.281, −0.201], p corrected = 0.026) and with attenuated amyloid accumulation over time ( β = −0.025, 95% HDI [−0.049, −0.001], p corrected = 0.039). In a sensitivity analysis excluding voxels with a high likelihood of substantial fiber crossing, the ALPS‐by‐time interaction for amyloid burden remained significant ( β = −0.028, 95% HDI [−0.052, −0.003], p corrected = 0.022), whereas the baseline association with Fazekas severity was attenuated ( β = −0.413, 95% HDI [−0.966, 0.181], p corrected = 0.751). Higher baseline WMH/ICV was associated with poorer baseline global cognition (PACC5) ( β = −0.092, 95% HDI [−0.177, −0.011], p corrected = 0.036), processing speed ( β = −0.116, 95% HDI [−0.223, −0.010], p corrected = 0.036), and executive function ( β = −0.144, 95% HDI [−0.251, −0.029], p corrected = 0.035). Higher baseline amyloid burden was associated with steeper PACC5 decline ( β = −0.065, 95% HDI [−0.096, −0.033], p corrected < 0.001). In cognitively normal older adults, higher conventional baseline ALPS was associated with lower Fazekas severity, although attenuation after crossing‐fiber adjustment indicates that this cross‐sectional relationship was sensitive to the microstructural composition of the ALPS regions. In contrast, higher baseline ALPS was associated with slower short‐term amyloid‐β accumulation, and this longitudinal association remained significant after crossing‐fiber adjustment. Greater baseline amyloid burden was associated with more rapid decline in global cognition, whereas higher baseline WMH volume was associated with poorer baseline global cognition, processing speed, and executive function. These findings support ALPS as a candidate noninvasive diffusion marker associated with longitudinal amyloid‐related change, while emphasizing the need for further validation of its relationship with SVD burden and its biological specificity.
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218270
Functional Outcomes and Safety of Endovascular Thrombectomy in Pediatric Acute Ischemic Stroke With Cardiac Abnormalities
Background and ObjectivesCardiac abnormalities are among the most common and complex risk factors of pediatric acute ischemic stroke (AIS). Although endovascular treatment (EVT) is increasingly use...
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218270
Functional Outcomes and Safety of Endovascular Thrombectomy in Pediatric Acute Ischemic Stroke With Cardiac Abnormalities
Background and ObjectivesCardiac abnormalities are among the most common and complex risk factors of pediatric acute ischemic stroke (AIS). Although endovascular treatment (EVT) is increasingly use...
- 5 April 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 80 (6) , 459-468
Predictive neuroimaging biomarkers of major depressive disorder treatment response: An umbrella review
Major depressive disorder (MDD) is a heterogeneous condition with varied responses to pharmacological, psychotherapeutic, and neuromodulation interventions. Identifying neuroimaging biomarkers predictive of treatment response could facilitate personalized treatment selection. This umbrella review synthesized findings from systematic reviews and meta‐analyses evaluating neuroimaging biomarkers predictive of treatment response in MDD. A comprehensive search was conducted across PubMed, Scopus, Web of Science, and Embase. Fourteen systematic reviews and meta‐analyses, encompassing 17,855 individuals with MDD, were included. Imaging modalities assessed included structural MRI, functional MRI (resting‐state and task‐based), diffusion tensor imaging, PET, MEG, and fNIRS. Methodological quality was evaluated using the Measurement Tool to Assess Systematic Reviews (AMSTAR 2 tool). The most consistently predictive biomarkers were increased volume and activity in the anterior cingulate cortex (ACC) and hippocampus and altered functional connectivity in the default mode network (DMN) and fronto‐limbic circuits. Predictive patterns varied by treatment modality: for example, larger hippocampal volume predicted pharmacotherapy response, while smaller hippocampal volume was associated with better outcomes in ECT. Machine learning models integrating multimodal data achieved high predictive accuracy (AUC >0.85), though most lacked external validation. Evidence quality was low to very low among the included studies due to methodological heterogeneity. Neuroimaging biomarkers, particularly involving ACC, hippocampus, and large‐scale functional networks, hold promise for guiding treatment selection in MDD. Integration of multimodal imaging and computational approaches may enhance predictive accuracy. However, standardization and prospective validation in clinical settings are needed for translation into practice.
- 5 April 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 80 (6) , 459-468
Predictive neuroimaging biomarkers of major depressive disorder treatment response: An umbrella review
Major depressive disorder (MDD) is a heterogeneous condition with varied responses to pharmacological, psychotherapeutic, and neuromodulation interventions. Identifying neuroimaging biomarkers predictive of treatment response could facilitate personalized treatment selection. This umbrella review synthesized findings from systematic reviews and meta‐analyses evaluating neuroimaging biomarkers predictive of treatment response in MDD. A comprehensive search was conducted across PubMed, Scopus, Web of Science, and Embase. Fourteen systematic reviews and meta‐analyses, encompassing 17,855 individuals with MDD, were included. Imaging modalities assessed included structural MRI, functional MRI (resting‐state and task‐based), diffusion tensor imaging, PET, MEG, and fNIRS. Methodological quality was evaluated using the Measurement Tool to Assess Systematic Reviews (AMSTAR 2 tool). The most consistently predictive biomarkers were increased volume and activity in the anterior cingulate cortex (ACC) and hippocampus and altered functional connectivity in the default mode network (DMN) and fronto‐limbic circuits. Predictive patterns varied by treatment modality: for example, larger hippocampal volume predicted pharmacotherapy response, while smaller hippocampal volume was associated with better outcomes in ECT. Machine learning models integrating multimodal data achieved high predictive accuracy (AUC >0.85), though most lacked external validation. Evidence quality was low to very low among the included studies due to methodological heterogeneity. Neuroimaging biomarkers, particularly involving ACC, hippocampus, and large‐scale functional networks, hold promise for guiding treatment selection in MDD. Integration of multimodal imaging and computational approaches may enhance predictive accuracy. However, standardization and prospective validation in clinical settings are needed for translation into practice.
- 8 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 972-979
Posterior cingulate cortex atrophy across the Alzheimer's disease spectrum: A cross-sectional MRI study linking volumetrics to cognitive decline
Background: The posterior cingulate cortex (PCC) is a metabolic hub within the default-mode network and an early target of Alzheimer's disease (AD) pathology, yet its quantitative relationship with cognition across the normal aging–mild cognitive impairment (MCI)–AD continuum remains incompletely defined. Objective: In this study we aimed to compare PCC volumes across AD, MCI, and controls, and assess their relationship with cognitive performance. Methods: In this single-center cross-sectional study, 161 participants (NL = 30, MCI = 60, AD = 71) underwent structural MRI. PCC volumes were automatically segmented and summed. Linear regressions adjusted for age and sex were performed to examine associations between PCC volumes and cognitive measures. False discovery rate correction was applied to multiple comparisons. Additional subgroup analyses were conducted by gender and education level using Mann–Whitney U tests, and ordinary least squares regression models tested for group × education interactions. Results: Mean Post-cin-T volume declined step-wise from NL (6.05 ± 0.21cm 3 ) to MCI (5.64 ± 0.63cm 3 ) to AD (4.98 ± 1.01cm 3 ; p < 0.001). Post-cin-R and Post-cin-L showed parallel gradients. Higher MoCA scores correlated with larger PCC volumes (e.g., total: β = 0.069, p < 0.001), whereas higher CDR scores were linked to smaller volumes (total: β = –0.705, p < 0.001). Subgroup analyses revealed that higher-education participants showed broader PCC–cognition associations. Interaction analyses indicated no significant moderating effect of education on group–volume relationships. Conclusions: Quantitative PCC atrophy differentiates NL, MCI and AD and correlates robustly with cognitive performance, particularly in educated individuals. PCC volumetry may serve as a non-invasive MRI biomarker for early diagnosis and disease staging in the AD spectrum.
- 8 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 972-979
Posterior cingulate cortex atrophy across the Alzheimer's disease spectrum: A cross-sectional MRI study linking volumetrics to cognitive decline
Background: The posterior cingulate cortex (PCC) is a metabolic hub within the default-mode network and an early target of Alzheimer's disease (AD) pathology, yet its quantitative relationship with cognition across the normal aging–mild cognitive impairment (MCI)–AD continuum remains incompletely defined. Objective: In this study we aimed to compare PCC volumes across AD, MCI, and controls, and assess their relationship with cognitive performance. Methods: In this single-center cross-sectional study, 161 participants (NL = 30, MCI = 60, AD = 71) underwent structural MRI. PCC volumes were automatically segmented and summed. Linear regressions adjusted for age and sex were performed to examine associations between PCC volumes and cognitive measures. False discovery rate correction was applied to multiple comparisons. Additional subgroup analyses were conducted by gender and education level using Mann–Whitney U tests, and ordinary least squares regression models tested for group × education interactions. Results: Mean Post-cin-T volume declined step-wise from NL (6.05 ± 0.21cm 3 ) to MCI (5.64 ± 0.63cm 3 ) to AD (4.98 ± 1.01cm 3 ; p < 0.001). Post-cin-R and Post-cin-L showed parallel gradients. Higher MoCA scores correlated with larger PCC volumes (e.g., total: β = 0.069, p < 0.001), whereas higher CDR scores were linked to smaller volumes (total: β = –0.705, p < 0.001). Subgroup analyses revealed that higher-education participants showed broader PCC–cognition associations. Interaction analyses indicated no significant moderating effect of education on group–volume relationships. Conclusions: Quantitative PCC atrophy differentiates NL, MCI and AD and correlates robustly with cognitive performance, particularly in educated individuals. PCC volumetry may serve as a non-invasive MRI biomarker for early diagnosis and disease staging in the AD spectrum.
- Open Access
- 28 November 2025
- Published by Springer Nature in BMC Medical Imaging
- Vol. 25 (1) , 496
Comparison of photon-counting CT angiography with energy-integrating CT angiography in coronary artery stenosis: a systematic review and meta-analysis
To perform CT-angiography of coronary arteries, energy-integrating detector computed tomography (EID-CT) is widely used but it has several limitations, esp
- 28 November 2025
- Published by Springer Nature in BMC Medical Imaging
- Vol. 25 (1) , 496
Open AccessComparison of photon-counting CT angiography with energy-integrating CT angiography in coronary artery stenosis: a systematic review and meta-analysis
To perform CT-angiography of coronary arteries, energy-integrating detector computed tomography (EID-CT) is widely used but it has several limitations, esp
- 30 October 2025
- Published by SAGE Publications in Interventional Neuroradiology
MRI quantitative biomarkers focusing on apparent diffusion coefficient for predicting hemorrhagic transformation after thrombectomy: A PRISMA-DTA systematic review and meta-analysis
Background: Hemorrhagic transformation (HT) is a serious complication following mechanical thrombectomy in acute ischemic stroke (AIS), significantly impacting clinical outcomes. Magnetic resonance imaging (MRI)-based quantitative biomarkers, particularly the apparent diffusion coefficient (ADC), have been investigated as predictors of HT, but findings across studies remain inconsistent. This study aimed to evaluate the diagnostic performance of quantitative MRI biomarkers, especially ADC values, for predicting any HT in AIS patients undergoing mechanical thrombectomy. Methods: A systematic search of PubMed, Embase, Scopus, and Web of Science was performed for studies published up to 20 July 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed by QUADAS-2. Eligible studies assessed quantitative biomarkers based on pre-treatment MRI for predicting any HT post-thrombectomy. Data on sensitivity, specificity, area under the curve (AUC), and other diagnostic metrics were extracted. Pooled estimates were calculated using a bivariate random-effects model. Heterogeneity was assessed via I² statistics, and publication bias was evaluated using Deeks’ funnel plot. Results: Eleven studies were included. The pooled sensitivity and specificity of models based on ADC for predicting HT were 0.75 (95% CI: 0.66–0.82, I²: 0%) and 0.73 (95% CI: 0.65–0.80, I²: 58.91%), respectively. The summary AUC was 0.79 (95% CI: 0.75–0.83), indicating strong diagnostic performance. Additional biomarkers such as infarct core volume, white matter hyperintensity and arterial spin labeling demonstrated potential but lacked sufficient data for meta-analysis. Conclusions: Diffusion-weighted imaging shows good diagnostic accuracy for predicting HT after mechanical thrombectomy. Integration of advanced imaging biomarkers into pre-thrombectomy protocols could enhance clinical decision-making and patient safety.
- 30 October 2025
- Published by SAGE Publications in Interventional Neuroradiology
MRI quantitative biomarkers focusing on apparent diffusion coefficient for predicting hemorrhagic transformation after thrombectomy: A PRISMA-DTA systematic review and meta-analysis
Background: Hemorrhagic transformation (HT) is a serious complication following mechanical thrombectomy in acute ischemic stroke (AIS), significantly impacting clinical outcomes. Magnetic resonance imaging (MRI)-based quantitative biomarkers, particularly the apparent diffusion coefficient (ADC), have been investigated as predictors of HT, but findings across studies remain inconsistent. This study aimed to evaluate the diagnostic performance of quantitative MRI biomarkers, especially ADC values, for predicting any HT in AIS patients undergoing mechanical thrombectomy. Methods: A systematic search of PubMed, Embase, Scopus, and Web of Science was performed for studies published up to 20 July 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed by QUADAS-2. Eligible studies assessed quantitative biomarkers based on pre-treatment MRI for predicting any HT post-thrombectomy. Data on sensitivity, specificity, area under the curve (AUC), and other diagnostic metrics were extracted. Pooled estimates were calculated using a bivariate random-effects model. Heterogeneity was assessed via I² statistics, and publication bias was evaluated using Deeks’ funnel plot. Results: Eleven studies were included. The pooled sensitivity and specificity of models based on ADC for predicting HT were 0.75 (95% CI: 0.66–0.82, I²: 0%) and 0.73 (95% CI: 0.65–0.80, I²: 58.91%), respectively. The summary AUC was 0.79 (95% CI: 0.75–0.83), indicating strong diagnostic performance. Additional biomarkers such as infarct core volume, white matter hyperintensity and arterial spin labeling demonstrated potential but lacked sufficient data for meta-analysis. Conclusions: Diffusion-weighted imaging shows good diagnostic accuracy for predicting HT after mechanical thrombectomy. Integration of advanced imaging biomarkers into pre-thrombectomy protocols could enhance clinical decision-making and patient safety.
- Open Access
- 26 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (2) , e70134
Development and validation of a combined clinical and MRI‐based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease
Background: Two of the most common complaints seen in neurology clinics are Alzheimer's disease (AD) and mild cognitive impairment (MCI), characterized by similar symptoms. The aim of this study was to develop and internally validate the diagnostic value of combined neurological and radiological predictors in differentiating mild AD from MCI as the outcome variable, which helps in preventing AD development.Methods: A cross‐sectional study of 161 participants was conducted in a general healthcare setting, including 30 controls, 71 mild AD, and 60 MCI. Binary logistic regression was used to identify predictors of interest, with collinearity assessment conducted prior to model development. Model performance was assessed through calibration, shrinkage, and decision‐curve analyses. Finally, the combined clinical and radiological model was compared to models utilizing only clinical or radiological predictors.Results: The final model included age, sex, education status, Montreal cognitive assessment, Global Cerebral Atrophy Index, Medial Temporal Atrophy Scale, mean hippocampal volume, and Posterior Parietal Atrophy Index, with the area under the curve of 0.978 (0.934–0.996). Internal validation methods did not show substantial reduction in diagnostic performance. Combined model showed higher diagnostic performance compared to clinical and radiological models alone. Decision curve analysis highlighted the usefulness of this model for differentiation across all probability levels.Conclusion: A combined clinical‐radiological model has excellent diagnostic performance in differentiating mild AD from MCI. Notably, the model leveraged straightforward neuroimaging markers, which are relatively simple to measure and interpret, suggesting that they could be integrated into practical, formula‐driven diagnostic workflows without requiring computationally intensive deep learning models.
- 26 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (2) , e70134
Open AccessDevelopment and validation of a combined clinical and MRI‐based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease
Background: Two of the most common complaints seen in neurology clinics are Alzheimer's disease (AD) and mild cognitive impairment (MCI), characterized by similar symptoms. The aim of this study was to develop and internally validate the diagnostic value of combined neurological and radiological predictors in differentiating mild AD from MCI as the outcome variable, which helps in preventing AD development.Methods: A cross‐sectional study of 161 participants was conducted in a general healthcare setting, including 30 controls, 71 mild AD, and 60 MCI. Binary logistic regression was used to identify predictors of interest, with collinearity assessment conducted prior to model development. Model performance was assessed through calibration, shrinkage, and decision‐curve analyses. Finally, the combined clinical and radiological model was compared to models utilizing only clinical or radiological predictors.Results: The final model included age, sex, education status, Montreal cognitive assessment, Global Cerebral Atrophy Index, Medial Temporal Atrophy Scale, mean hippocampal volume, and Posterior Parietal Atrophy Index, with the area under the curve of 0.978 (0.934–0.996). Internal validation methods did not show substantial reduction in diagnostic performance. Combined model showed higher diagnostic performance compared to clinical and radiological models alone. Decision curve analysis highlighted the usefulness of this model for differentiation across all probability levels.Conclusion: A combined clinical‐radiological model has excellent diagnostic performance in differentiating mild AD from MCI. Notably, the model leveraged straightforward neuroimaging markers, which are relatively simple to measure and interpret, suggesting that they could be integrated into practical, formula‐driven diagnostic workflows without requiring computationally intensive deep learning models.
- 26 May 2025
- Published by S. Karger AG in Neuroepidemiology
- Vol. 60 (2) , 239-256
Burden of Neurological Disorders in Children and Adolescents (<20 Years Old) in North Africa and the Middle East from 1990 to 2021
Background: Neurological disorders impose a significant health burden globally, particularly in regions like North Africa and the Middle East (NAME) with unique healthcare and societal challenges. Despite progress in addressing neurological conditions, understanding the burden in pediatric and adolescent populations remains limited. This study analyzes the trends and burden of neurological conditions in individuals under 20 years old across the NAME super region from 1990 to 2021 using Global Burden of Disease (GBD) data. Methods: GBD 2021 data were analyzed to assess prevalence, incidence, years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and mortality rates. The data were stratified by age, sex, and sociodemographic index (SDI). Population attributable fraction was used to estimate the burden attributable to risk factors, and uncertainty intervals (UIs) were calculated using 500 posterior draws, reporting 95% UIs based on the 2.5th and 97.5th percentiles. All visualizations and analyses were conducted using Python (version 3.12.4). Results: Neurological condition prevalence in 2021 was 21,797.5 per 100,000, with tension-type headaches and migraines accounting for the majority of cases. Idiopathic epilepsy remained a leading cause of mortality, although it had a decrease of −50.9% in YLLs compared to 1990. Migraine affected about 9,161.9 per 100,000, increasing by 9.9% from 1990. It also accounted for the highest YLD rate (350.9). Despite decreases in YLLs and deaths, YLDs showed minimal change. Similarly, DALYs did not show significant change from 1990 (17.9%; 95% UI: −12.17 to 36.05). Higher SDI was associated with reduced DALYs but increased prevalence and YLDs. Conclusion: The burden of neurological disorders in pediatric and adolescent populations in NAME highlights regional disparities and the need for targeted healthcare strategies. Enhanced screening, early diagnosis, and management are essential to reducing the burden of these disorders.
- 26 May 2025
- Published by S. Karger AG in Neuroepidemiology
- Vol. 60 (2) , 239-256
Burden of Neurological Disorders in Children and Adolescents (<20 Years Old) in North Africa and the Middle East from 1990 to 2021
Background: Neurological disorders impose a significant health burden globally, particularly in regions like North Africa and the Middle East (NAME) with unique healthcare and societal challenges. Despite progress in addressing neurological conditions, understanding the burden in pediatric and adolescent populations remains limited. This study analyzes the trends and burden of neurological conditions in individuals under 20 years old across the NAME super region from 1990 to 2021 using Global Burden of Disease (GBD) data. Methods: GBD 2021 data were analyzed to assess prevalence, incidence, years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and mortality rates. The data were stratified by age, sex, and sociodemographic index (SDI). Population attributable fraction was used to estimate the burden attributable to risk factors, and uncertainty intervals (UIs) were calculated using 500 posterior draws, reporting 95% UIs based on the 2.5th and 97.5th percentiles. All visualizations and analyses were conducted using Python (version 3.12.4). Results: Neurological condition prevalence in 2021 was 21,797.5 per 100,000, with tension-type headaches and migraines accounting for the majority of cases. Idiopathic epilepsy remained a leading cause of mortality, although it had a decrease of −50.9% in YLLs compared to 1990. Migraine affected about 9,161.9 per 100,000, increasing by 9.9% from 1990. It also accounted for the highest YLD rate (350.9). Despite decreases in YLLs and deaths, YLDs showed minimal change. Similarly, DALYs did not show significant change from 1990 (17.9%; 95% UI: −12.17 to 36.05). Higher SDI was associated with reduced DALYs but increased prevalence and YLDs. Conclusion: The burden of neurological disorders in pediatric and adolescent populations in NAME highlights regional disparities and the need for targeted healthcare strategies. Enhanced screening, early diagnosis, and management are essential to reducing the burden of these disorders.
- Open Access
- 4 March 2025
- Published by MDPI AG in Preprints.org
Death-Awareness in Artificial Intelligence: Its Possibility Based on Heidegger's View and Its Importance in Medicine
With the rise of artificial intelligence (AI) in medicine, a central debate has emerged regarding whether AI can replace physicians. While previous studies have examined AI’s limitations in areas such as self-awareness and language processing, this study explores a novel dimension: the possibility of death-awareness in AI and its implications for the physician-patient relationship. Death-awareness is fundamental to medical practice, allowing physicians to empathize with patients, acknowledge existential fears, and support autonomy in end-of-life decision-making. Using Heidegger’s concept of Dasein, this paper examines whether AI, through its evolving cognitive capabilities, can develop an authentic understanding of mortality.A phenomenological approach is applied to assess AI’s ability to experience being-towards-death (Sein-zum-Tode), a characteristic central to human authenticity. Heidegger argues that Dasein’s existence is shaped by its awareness of finitude, which fosters existential anxiety and authenticity. However, AI, lacking organic mortality and intrinsic self-awareness, does not experience the temporality and vulnerability that define Dasein. While AI demonstrates learning, adaptation, and responsiveness, its decision-making remains fundamentally preprogrammed and detached from existential meaning. Although recent advancements in neural networks, embodied AI, and reinforcement learning have allowed AI to engage with the world dynamically, it does not yet possess mood, fear, or the anticipation of its own non-existence—key components of Heideggerian authenticity.The study concludes that while AI may achieve functional competence in medicine, it lacks the ontological depth necessary for true humanistic care. Future discussions on AI in healthcare must go beyond performance metrics and consider the existential and ethical dimensions of AI-driven decision-making. If AI were ever to attain true death-awareness, it would challenge the very boundaries between human and machine, raising profound implications for medicine, ethics, and the philosophy of artificial intelligence.
- 4 March 2025
- Published by MDPI AG in Preprints.org
Open AccessDeath-Awareness in Artificial Intelligence: Its Possibility Based on Heidegger's View and Its Importance in Medicine
With the rise of artificial intelligence (AI) in medicine, a central debate has emerged regarding whether AI can replace physicians. While previous studies have examined AI’s limitations in areas such as self-awareness and language processing, this study explores a novel dimension: the possibility of death-awareness in AI and its implications for the physician-patient relationship. Death-awareness is fundamental to medical practice, allowing physicians to empathize with patients, acknowledge existential fears, and support autonomy in end-of-life decision-making. Using Heidegger’s concept of Dasein, this paper examines whether AI, through its evolving cognitive capabilities, can develop an authentic understanding of mortality.A phenomenological approach is applied to assess AI’s ability to experience being-towards-death (Sein-zum-Tode), a characteristic central to human authenticity. Heidegger argues that Dasein’s existence is shaped by its awareness of finitude, which fosters existential anxiety and authenticity. However, AI, lacking organic mortality and intrinsic self-awareness, does not experience the temporality and vulnerability that define Dasein. While AI demonstrates learning, adaptation, and responsiveness, its decision-making remains fundamentally preprogrammed and detached from existential meaning. Although recent advancements in neural networks, embodied AI, and reinforcement learning have allowed AI to engage with the world dynamically, it does not yet possess mood, fear, or the anticipation of its own non-existence—key components of Heideggerian authenticity.The study concludes that while AI may achieve functional competence in medicine, it lacks the ontological depth necessary for true humanistic care. Future discussions on AI in healthcare must go beyond performance metrics and consider the existential and ethical dimensions of AI-driven decision-making. If AI were ever to attain true death-awareness, it would challenge the very boundaries between human and machine, raising profound implications for medicine, ethics, and the philosophy of artificial intelligence.
- Open Access
- 11 February 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (2) , e70143
Ultrasound‐Guided Percutaneous Sclerotherapy With Bleomycin for Management of Infantile Subcutaneous Hemangioma: A Case Report
Percutaneous sclerotherapy with bleomycin is an effective, minimally invasive treatment for aggressive pediatric hemangiomas, especially when traditional therapies fail. This approach can improve clinical outcomes, including thrombocytopenia resolution and tumor size reduction, with minimal systemic side effects.
- 11 February 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (2) , e70143
Open AccessUltrasound‐Guided Percutaneous Sclerotherapy With Bleomycin for Management of Infantile Subcutaneous Hemangioma: A Case Report
Percutaneous sclerotherapy with bleomycin is an effective, minimally invasive treatment for aggressive pediatric hemangiomas, especially when traditional therapies fail. This approach can improve clinical outcomes, including thrombocytopenia resolution and tumor size reduction, with minimal systemic side effects.